home / stock / allo / allo news

ALLO News and Press, Allogene Therapeutics Inc.

Stock Information
Company Name: Allogene Therapeutics Inc.
Stock Symbol: ALLO
Market: NASDAQ
Website: allogene.com
Menu
ALLO ALLO Quote ALLO Short ALLO News ALLO Articles ALLO Message Board
Get ALLO Alerts

News, Short Squeeze, Breakout and More Instantly...
ALLO - Allogene Therapeutics Activates Three Community Cancer Centers as First Sites for the Pivotal Phase 2 ALPHA3 Trial Evaluating Cemacabtagene Ansegedleucel (cema-cel) as First Line (1L) Consolidation Treatment for Patients with Large B-Cell Lymphoma (LBCL)

Patient Screening is Underway at Rocky Mountain Cancer Centers, Part of the US Oncology Network and Sarah Cannon Research Institute; Astera Cancer Care, Part of the OneOncology Network; and Norton Cancer Institute ALPHA3 Will be the First Pivotal Trial to Offer CAR T as Part of First Line (...
ALLO - Allogene: Two End Of 2024 Data Readouts With Improved Allogeneic CAR-T Products

2024-06-12 13:09:17 ET Summary Allogene Therapeutics, Inc. initiation of phase 2 ALPHA3 study, using cema-cel for the treatment of patients with 1st-line large B-cell lymphoma, expected in mid-2024 with two data analysis in 2026. Results from phase 2 ALPHA2 trial, using cema-cel f...

ALLO - Cellectis: 2 Data Readouts Of Blood Cancer Studies By End Of 2024

2024-05-30 09:14:24 ET Summary Data update from phase 1 BALLI-01 study, using UCART22 for the treatment of B-cell acute lymphoblastic leukemia, expected by the end of 2024. The global acute lymphoblastic leukemia therapeutics market is expected to increase to $8.29 billion by 2032...

ALLO - Nkarta: A Look Into Q1 Results And Upcoming Catalysts

2024-05-23 11:48:35 ET Summary Nkarta, Inc. has raised $240.1 million through a stock offering, strengthening its cash position and extending its cash runway to 2027. The company's stock has been trending down, but there are signs of recovery, with a 6.4% increase in share price. ...
ALLO - Allogene Therapeutics Announces Participation in the TD Cowen 5th Annual Oncology Innovation Summit

SOUTH SAN FRANCISCO, Calif., May 23, 2024 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer and autoimmune disease, today announced it will participate in th...

ALLO - ASTS, ALLO and CMCM are among premarket gainers

2024-05-21 08:26:04 ET More on premarket gainers & stock LM Funding America, Inc. (LMFA) Q1 2024 Earnings Call Transcript LM Funding America, Inc. (LMFA) Q4 2023 Earnings Call Transcript BriaCell falls on $5M stock offering LM Funding America mines 24.7 b...

ALLO - Allogene Therapeutics, Inc. (ALLO) Q1 2024 Earnings Call Transcript

2024-05-13 19:31:09 ET Allogene Therapeutics, Inc. (ALLO) Q1 2024 Earnings Conference Call May 13, 2024, 05:00 PM ET Company Participants Christine Cassiano - Chief Corporate Affairs & Brand Strategy Officer David Chang - President & Chief Executive Officer ...
ALLO - INFN, VYGR and AMSC are among after hour movers

2024-05-13 17:06:07 ET Gainers: Harrow ( HROW ) +15% . Fulcrum Therapeutics ( FULC ) +7% . Allogene Therapeutics ( ALLO ) +6% . Infinera Corporation ( INFN ) +6% . Voyager Therapeutics ( VYGR ) +5% . Losers: Akoya BioScie...

ALLO - Allogene Therapeutics announces pricing of $110M offering of common stock

2024-05-13 16:59:14 ET More on Allogene Therapeutics Allogene Therapeutics: 2024 Platform Vision Sings Mid-Term Upside Allogene Therapeutics, Inc. (ALLO) Q4 2023 Earnings Call Transcript Allogene Therapeutics Q1 2024 Earnings Preview Allogene Therapeutics GAA...

ALLO - Allogene Therapeutics Announces Pricing of $110 million Offering of Common Stock

SOUTH SAN FRANCISCO, Calif., May 13, 2024 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer and autoimmune disease, today announced the pricing of an underwr...
Next 10